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Abstract 
Triple negative breast cancer is an aggressive family of cancers that are extremely difficult to 
treat. Therefore, the prognosis for most patients with TNBC is poor. The goal of this rese<trch is 
to determine if photodynamic therapy could be a possible therapy option for TNBC in the future 
using MDA-MB23l cells. MDA-MB231 cells were originally isolated from a p<ttient with triple 
neg<~tive bre<tst cancer and have been used for many sludit:s, so they would work well for this 
study. Photodynamic therapy uses compounds called photosensitizing ag~nts which art: taken up 
by all tissues in the body and then activated by light. This creates a reactive oxygen species in 
the cell which is thought to cause cell death. To quantify cell death, an MTT assay was 
perfonned. The assay showed concentration-dependent cell death in the plates that were exposed 
to light. The plates that weren't exposed to light showed some dark toxicity at the highest 
concentrations. However, the cell death due to dark toxicity is small compared to cell death seen 
in the cells exposed to light. In addition to measuring cell death, experiments were performed to 
determine the mechanism of cell death. Antibodies were used to stain the cell tor DNA 
fragmentation, which is a sign of apoptosis. The cells were also co-stained with four antibodies 
to test for the mechanism of cell death. The results from the antil?ody-staining assays suggested 
that the cells were dying mostly by caspase-mediated apoptosis. In addition, staining for 
oxidative dam<Jge and ctutophagy were also seen. 
History of Photodynamic Therapy 
Photodynamic therapy is a relatively new idea and practice. lt was "accidentally" discovered 
over 100 years ago by a medical student by the name of Oscar Raab [ 1]. Raab was studying the 
effects of fluorescent dyes on infusoria, which are a class of microorganisms. He found that 
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when intense light was applied to the dyes, the microorganisms were rapidly destroyed. From 
there, Raab's professors took over and furthered studied this process. His professors, Jesionek 
and von Tappeiner, described and named this process, now known as photodynamic therapy, or 
PDT [11. 
By the early 1900s, patients were successfully being treated for various cancers, 
particularly of the skin, by PDT. Although PDT had shown promising results, it was not abl.e to 
build enough momentum and died out until about 50 years later. In the 1960s, PDT was 
rediscovered by Lipson and Schwartz through studies done at the Mayo Clinic [5]. These studies 
not only showed tumor ablation, but also showed the ability of photosensitizing agents to 
fluoresce and define the boundaries of tumors. Then, in the 1970s, a scientist by the name of 
Dougherty began working with porpllyrin compounds for PDT. With this knowledge and 
experience, Dough~rty was able to produce a commercially suitable photosensitizing drug, 
reliable light sources, and appropriate clinical trials that proved the value of PDT to the oncology 
community [I J. For this reason, Dougherty is known by many as the "The Father of PDT." 
Background 
Triple-negative breast cancer (TNBC) is an aggressive set of cancers that have few promising 
therapy options. Because of this, the prognosis for most cases ofTNBC is very poor. Typically, 
TNBC is found as an advanced stage disease and patients have low survival rates compared to 
other types of breast cancer. The goal of our research is to detennine whether photodynamic 
therapy is a viable option for treating TNBC in the future. 
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TNBC is described as any breast cancer that is lacking in expression of estrogen receptor 
(ER), progesterone receptor (PgR) and of HER2 overexpression. This cancer accounts for about 
15% of all breast cancer [ 4 ]. TNBC is usually found as high-grade tumors, although there have 
been cases of low-grade tumors found. This is most likely due to the fact that TNBC tumors are 
typically very difficult to find through mammography [ 4]. There are many risk factors that are 
seen with TNBC's. This cancer occurs more frequently in patients younger than 50 years old. In 
addition, TNBC is seen 2 lo 3 times more often in African Americans than other racial groups in 
the United States. Other important risk factors involved include a strong family history of breast 
cancer, young age at firsl birth, multiparity, and a high waist:hip ratio [3]. 
TNBC's, in addition to Jacking ER, PgR, and HER2 expression, show many other 
p<~thological features. TNBC comprises<~ heterogeneous subgroup of tumors including basal-like 
and claudin-low subtypes. In addition, these tumors c<~n be of ductal type, metaplastic, 
medullary, or adenoid cystic type. TNBC's frequently express basal cytokcratins and the 
epide&mal growth factor receptor (EGFR) Hl:!Rl which <~re features that are usually associated 
with a poor prognosis in breast cancer. TNBC also shows overlap with basal-like and BRCA-1 
cancers. The BRCA -1 protein plays a role in DNA repair and transcriptional regulation [ 4]. This 
may promote genetic instability and favor tumor growth, and BRCA-1 tumors account for about 
5% of all breast cancers [ 4]. Both BRCA I and TNBC tumors have been shown through 
immunohistochemical (THC) analyses to be associated with high Ki-67 expression, p53 mutation, 
and basal-like expression. In addition, greater than 50% ofBRCA-1 carriers have TNBC [4]. 
Therefore, people with a BRCA 1 mutation are at higher risk of developing TNHC. 
Perhaps one of the most disappointing things about TNBC is the fact that there are 
currently no specific treatment options. In other cases of breast cancer, hormonal therapy is a 
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viable option. However, since TNBC's lack the receptors that are the usual targets in honnonal 
therapy, this will not work. TNBC is also not a candidate for agents such <ts trastuzumab, which 
is a HER-2 directed <~gent (4]. As of right now, the only viable option for treating TNBC is 
chemotherapy, which is not a very effective or friendly treatment option. Because of the lack of 
treatment options, the survival rates for TNBC's are generally lower than other types of cancer. 
In a study done by the Californi<t Cancer Regist1y, TNBC's were present at a more <~dvanced 
stage disease and had lower 5-year survival rates (77% vs. 93%) than non-TNBC cancers [4]. 
TNBC's also tend to show a characteristic pattem of early relapse and shorter overall survival in 
patients [3]. For these reasons, it is important to tind a viable treatment option for triple m:gative 
breast cancer. 
One therapy option that may be a viable treatment for TNBC is photodynamic therapy 
(PDT). PDT is a method of destroying cells through the use of molecules called photosensitizers 
(PS) and light. Cells take up the PS, and, when exposed to light of a speci fie wavelength, create a 
photodynamic reaction (PDR) which causes the cell to die [I]. Although it is not known for sure 
how the cell dies during the PDR, studies have determined a basic idea of how PDT works in the 
cell. Once light is applied to the cell, the energy from the light alters the PS via energy transfer 
from the photon to the PS [I]. There are a few pathways in which the PS can lose energy, 
however, the most important pathway for clinical PDT is the generation of a type II 
photochemical reaction [I]. In this pathway, the PS interacts with oxygen to generate singlet 
oxygen, which then destroys the cell through oxidative damage. In addition, the tumor could die 
through ablation of the cells of the vasculature that supplies the tumor or could initiate a immune 
response to the tumor cells. 
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To make sure that PDT gives the best possible treatment results tor cancer, there are 
many characteristics PS agents need to be successful. Some of the most important characteristics 
of PS agents are: nontoxic until activated by light, hydrophilic properties for easy application, 
activated by a useful wavelength of light, and a reliable generator of the PDR I_ II. Successful PS 
agents should also concentrate in the tumor cells only and not healthy cells, should leave the 
patient's body fairly quickly, should not create any toxic by-products, and should provide a pain-
free therapy [ 1]. This is a long list of characterif'tics of PS agents, and finding one that checks all 
the boxes is difficult. Currently, there arc several PS agents on the market such as 
Hematoporphyrin derivative {HPD), Foscan, Mono-L-aspanyt chlorin e6, aminolevulinic acid, 
and Fotosens [I]. Although all of these arc able to create a PDR to kill cells, each of them have 
their drawbacks. For example, HPD is non-toxic and docs not cause pain, but, it stays in the body 
for 6 to 8 weeks after introduction. During this time, patients must stay out of a strong light 
source, like intense sunlight, to avoid severe bums [ 1]. This is not the most ideal situation for the 
patient alter cancer treatment. Another PS agent that is very similar to the agents used in this 
paper is Foscan. Foscan is a plant based chlorin derivative that produces a rapid and significant 
PDR [I]. The drug is so active that patients must stay in a dark room for 24 hours after treatment 
to avoid severe bums to the body. PS agents that are used today are also not cancer cell-specific, 
which means that the PS agents are taken up by all cells. In the clinic, this can be compensated 
for by only shining light on the tumor itself. However, if the PS agent stays in the body for a long 
period after treatment, the patient has to avoid other strong sources of light. The treatment using 
Foscan is also very painful, so patients must undergo anesthesia during treatment [ 1]. However, 
Foscan is still a popular drug of choice for PDT because of its effectiveness in killing tumor 
cells. 
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For this study, PS agents known as porphyrins were tested. Porphyrins, as mentioned 
earlier, are very similar to Foscan in structure. They consist of a hydrophobic ring structure, as 
shown in Figure I. 
R R 
Figure 1 - Porphyrin ring structure 
This very hydrophobic ring is thought to help the molecule enter the cell. The four R 
groups attached to the ring structure are what differentiates porphyrins trom one another. These 
R groups are usually hydrophilic and polar to allow for easier travel through the blood. Foscan, a 
chlorin, differs from porphyrins by having one less double bond in the ring structure. The R 
group tor Fosean is shown Figure 2. 
OH 
~ 
Figure 2 - R group in Foscan 
In this paper, Foscan was used as a comparison for the porphyrins that were tested in the 
ICJb. Two important criteria that were analyzed were the LD5uand the dark toxicity of the 
porphyrins. 
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TNBC is a very aggressive type of cancer that has few viable treatment options. The 
prognosis is generally poor for patients with TNBC and patients have lower survival rates 
compared to patients with other types of breast cancer. For these reasons, it is important to find 
better treatment options. This study looks at photodynamic therapy using porphyrins as a 
potential treatment option. 
Materials and Methods 
For this study, MDA-MB231 triple negative breast cancer cells were grown in 
MEM/10% FBS/2mM L-glutamine/pen-strep at 37°C. These cells were used in the experiments 
to test porphyrin effectiveness. For the assays, the cells were plated in 96-well plates. The 
porphyrin derivatives tested in this study were synthesized by Dr. Joe Bradshaw's lab at 
Ouachita Baptist University. These porphyrins were H2TPP-A40H, H2TPP-A50H, and H2TPP-
A60H. The structures of their R groups arc shown in Figure 3. 
0 H 
-o-Il l C-1'11~0H 
H!TPP-A40H 
0 H 
-o- Il I C~~OI1 
H2TPP-A60H 
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Figure 3- R groups of porphyrins tested 
For the photodynamic treatments of the cells, the porphyrins were diluted in 2 ml of 
growth medium to the desired concentration. These concentrations were added to the cells in the 
96-wcll plates once the cells were about 25% confluent. Eight wells were used for each 
condition. Twenty-four hours after adding the porphyrins to the cells, the medium was replaced 
with fresh medium to remove any porphyrins not in the cells. One plate was then exposed to 
white light (0.5 J/cm1) for 16 mins and then was moved to the incubator in the dark. The second 
plate was placed in the incubator in the dark immediately after replacing the medium. MTT 
assays were then done three days later. 
To test tor cell viability, MTT assays were performed for each plate. The MTT assays 
test the viability of the cells by using a yellow chemical called MTT. The cells will n:duce the 
yellow MTT to a purple formazan, which can be dissolved in DMSO. The more purple the 
solution in the wells, the more viable the cells. The absorbance of each plate was measured in a 
plate reader at 570 nrn with a 630 nm correction. The averages and standard deviations for each 
condition were then calculated and graphed. 
To test for the mechanism of cell death, a TUNEL assay was performed at the University 
of Arkansas for Medical Sciences (UAMS). The cells were plated in 8-well chamber slides and 
were treated with H1TPP-PipOH at the LD50 tor 24 hours. PipOH had been previously tested and 
had shown effectiveness as a PS agent, so it was used in this assay instead of the other 
compounds that were used in this study. The cells were then exposed to light in the same way as 
the 96-well plates. Twenty-four hours after exposure, the cells were washed using PBS 
(phosphate buffered saline) and fixed with a 4% PFA-based buffered solution. Paraformaldehyde 
(PF A) is converted into formaldehyde by PBS in solution. Formaldehyde then terminates all 
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ongoing biochemical reactions in the cells and increase the cells' stability. This is call~::d "fixing" 
c~::lls. A TUNEL assay stains the cells for DNA fragmentation. In addition, the celts were co-
stained with DAPI and four antibodies: Caspasc-3, EndoG, OGG I, and HOI. These antibodies 
slain for cell death mechanisms such as apoptosis, autophagy, and oxidative damage. Caspase-3 
is a marker for many apoptotic pathways, so if it is seen the cell most likely died due to 
apoptosis. Endo-G is at.:tivated in caspase-independent apoptosis. OGG I stains for nuclear 
oxidative damage, which occurs when the nucleus is damaged by reactive oxygen species, while 
HOI stains for oxidative damage. Since the mechanism of PDT involves reactive oxygen 
species, these antibodies are expected to stain in the cells exposed to light. 
Results 
The porphyrins H~.TPP-A40H, H1TPP-A50H, and H!TPP-A60H were test~d for their 
cell toxicity in this study. After three separate experiments of the porphyrins on cells, the cell 
viability values were averaged and graphed together. The standard deviations of these values 
were also found. Figure 4 shows the graphs of each porphyrin and an overlay of the three 
porphyrins together. 
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Figure 4- Graph A shows the cell viability for A40H; Graph B shows the cell viability for 
ASOH; Graph C shows the cell viability for A60H; Graph D shows the three porphyrins 
together. 
The results indicate the porphyrins showed concentration-dependent cell death when 
exposed to light. The LDso was in the 10-20 JiM range for each of them. One thing to note is that 
at concentrations needed to kill >80% of the cells, significant dark toxicity was seen. 
The TUNEL assay done at UAMS showed some insight into how the cells treated with 
these porphyrin derivatives were dying. Figure 5 shows a graph of the mean intensity of OGG l 
staining in cells treated with porphyrin and light. 
II 
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Figure 5 
These results show that there was a significant increase in the amount of OGG 1 staining, 
which shows oxidative damage, in cells that were both exposed to PipOH and tight as compared 
to cells that had no porphyrin and cells that were not exposed to light. 
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Figure 6 
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This graph indicates that a higher percentage of cells that were exposed to PipOH and 
light showed both higher amounts of DNA fragmentation and higher amounts of Caspase-3. This 
could indicate that the cells are dying through apoptosis. 
Figure 7 shows the merged staining picture of the cells that were exposed to PipOH and 
light. The cells in this figure were stained with TUNEL and co-stained with DAPI and Caspase-
3. This figure shows that the cells expressed Caspase-3 and were TUNEL-positive due to the 
blue and bright orange stains, respectively. 
Figure 7- The red staining shows Caspasc-3, the blue staining shows OAPI, and the bright 
orange stain is for TUNEL. 
Discussion 
This study showed that the porphyrins used were effective in killing triple negative breast 
cancer cells when exposed to light. The graphs in Figure 4 show concentration-dependent cell 
death with a LD~o in the l0-20 11M range. These porphyrins conLained monohydroxy side chains, 
which means that the had only one hydroxyl (-OH) group. These results were compared to 
results obtained from testing the effectiveness of polyhydroxy side chain porphyrins (more than 
one -OH group) (data not shown). The polyhydroxy side chains differed from the monohydroxy 
side chains shown here in that the LDso was much greater ( 40-50 ~LM). Another difference 
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between the two families was that the polyhydroxy side chains showed little to no dark toxicity 
at any concentration, whereas the monohydroxy side chains showed dark toxicity at the higher 
concentrations. 
From the TUNEL assay, the results indicate that the cells exposed to the porphyrin 
PipOH were dying mainly through caspase-mcdiatcd apoptosis, as well as oxidative damage. 
Since PDT is known to create reactive oxygen species within the cell, oxidative damage was 
expected to be seen. Figure 5 shows the staining of OGG 1, which is a marker seen in cells that 
have gone through oxidative damage. As expected, the graph shows a higher amount of staining 
in the cells that were exposed to both the porphyrin and light as opposed to cells that were not 
exposed to the porphyrin and cells thClt were not exposed to light. Figures 6 and 7 suggest that 
the cells died by cClspase-mediated Clpoptosis. The graph in Figure 6 shows a greater staining of 
TUNEL positive cells and Caspase-3 in cells exposed to PipOH and light. One interesting note 
about Figure 6 is that there is a greater percentage of cells showing TUNEL and Caspase-3 that 
were exposed to th~ porphyrin but no light. Through the cell viability assays, it is known that 
these cells did not die, however. This could indicate the cells may have been "preparing" for 
death hy increasing the expression ofCClspase-3. How~ver, since there was no light given to the 
cells, they did not go through apoptosis. 
The porphyrins tested here show great promise in being potential options for treClting 
triple negative breast cancer in the future. However, more testing needs to be done in order to 
fully know the effect of these drugs. Since porphyrins are taken up by all cells and not just 
cancer cells, research on the pharmacokinetics needs to be done. This research would show how 
the drugs interact with the human body and how long they stay in the human body. This would 
also show any by-products the porphyrins degrade into; these products cannot be toxic to the 
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human body for these porphyrins to be successful PS agents. The TUNEL assays were extremely 
enlightening as to how these drugs kill the cells. It is important to know how the cells are dying 
to best formulate an effective treatment plan for patient use. 
Conclusions 
Triple negative breast c;;mcer is an extremely aggressive form of cancer with few viable 
tr~atment options. On~ potential oplion explored in this study was photodynamic therapy. 
R~sults showed that the porphyrins tested have promise in becoming drugs for cancer treatment. 
The drugs killed cells that were exposed to light at low concentrations; the LOso was in the I 0-20 
J.l.M range. These porphyrins also showed no dark toxicity in lower concentrations, however 
some dark toxicity was seen in cells that were given higher concentrations. TUNEL assays were 
also performed to dctcnninc the mechanism of cell death. Results showed that the cells were 
likely dying through caspasc-mcdiatcd apoptosis. In the future, we would like to repeat the 
TUNEL experiments using t1ow cytomctry to receive a better picture of the staining of the cells 
that detached from the surface of the plate. This would give a better representation of the fraction 
of cells that died due to apoptosis, necrosis, or another mechanism. 
Other Uses of Photodynamic Therapy 
Although the main focus of this paper is using PDT on breast cancer, PDT has been used to treat 
other ailments as well. Using PDT to treat severe acne is something that researchers are looking 
into currently [2]. Although it is only in clinical trials, researchers believe that PDT shows 
promise in being able to treat severe acne in the future. In addition, PDT is used to treat other 
types of cancer, such as skin cancer, esophageal cancer, and gastric cancer. Skin cancer is an 
especially popular choice for PDT treatment because of the easy access to the tumor. 
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Illuminating a tumor within the body with light is not ao;; simple as a tumor on the skin. 
Therefore, PDT has shown major success in treating skin cancers. One specific drug used to treat 
skin cancer is called aminolevulinic acid (ALA). This photosensitizer is enzymatically converted 
into Proto-Porphyrin I X, which is a powerful photosensitizing agent [ 1 ]. This means that the 
ALA can be applied to the skin topically, and then the body itself produces the drug from the 
ALA. Once this happens, the tumor can be illuminated and thus killed very easily. For this 
reason of ease of access, skin cancer is one of the more promising options for PDT treatment 
going forward. 
Perhaps one of the most promising directions that PDT is headed is 
photoimmunotherapy. Photoimmunotherapy is a response to POT's biggest weakness as a cancer 
treatment, which is its non-spcciticity. Photoscnsitizers used in PDT are not specific to cancer 
cells. This means that the drug is taken up by all the cells of the body, not just the cancer cells. 
This makes treatment very tricky; if healthy cells are illuminated by enough light, then those 
cells will die. The desired outcome of PDT is for only cancer cells to be killed by the treatment, 
however there is always a good chance that the desired outcome is not what happens. 
Photoimmunotherapy utilizes a monoclonal antibody that it is specific to targets on the 
cancer cell membrane [2]. Scientists have also been able to add drugs to these antibodies to fonn 
complexes that not only find and bind to cancer cells, but also kill the cells. One study created a 
specific dye that was attached to a monoclonal antibody. Once the complex was bound to the 
cancer cell, a light of a wavelength of 690 nm was used to illuminate the cancer tissue. The lighl 
activated the dye portion of the complex, which changed the molecular makeup of the dye. This 
caused the cancer cell membrane to break apart, thus killing the cell [2]. 
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This treatment, unlike PDT, is very new to the medical community. However, this 
process shows immense promise in tre<~ting cancer in patients much more efficiently. Although it 
is not exactly PDT, photoimmunotherapy is extremely simil<~r and uses PDT mechanisms. 
Future of PDT 
As mentioned earlier, PDT has shown major promise as a treatment for cancer and other diseases 
in the future. PDT as a cancer treatment is one of the most interesting avenues it can take 
because of its comparison to other treatment options. For many cancers, including triple negative 
breast cancer, there are no specific treatments. The only way to treat these cancers is through 
radiation and chemotherapy. These processes arc extremely ham1ful to the body as a whole and 
affect the patient greatly. Although PDT has its flaws, many believe it is and will be a better 
option for cancer treatment in the future. 
A major aspect of PDT that scientists can improve on for the future is finding a great 
photosensitizing agent. Many problems with PDT arise from the drugs used not fitting all of the 
criteria of a "perfect" PS agent, such as toxicity, specificity, and light absorption. This is what 
the main focus of this study was. If better and better PS agents can be synthesized and used in 
PDT, this therapy option will continue to grow in popularity in treating cancer and other 
diseases. 
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